atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
Posted:
Atai Life Sciences a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day. Read more here.
In Beetroot latest panel, they delved into the essence of the Corporate Sustainability Reporting Directive (CSRD) with Klaudia Shevelyuk, Johan Löfquist, Pete Jefferson, Rana Ersgård, and Sebastian Streiffert.
The conversation covered not just what CSRD means for businesses but also the role…
Join Health Innovation Network Masterclass webinar on 13 May on how to prescribe safely for older people with guest speaker: Dr Lauren Walker, Senior Clinical Lecturer in Clinical Pharmacology and Therapeutics and Internal Medicine, University of Liverpool
Book your place here.
Attendees
Sponsors and
Exhibitors
Media
Contact us